Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program

• Published in: Journal of hepatology Vol. 61; no. 5; pp. 976 - 983
• Main Authors: Colombo, Massimo, Strasser, Simone, Moreno, Christophe, Abrao Ferreira, Paulo, Urbanek, Petr, Fernández, Inmaculada, Abdurakmonov, Djamal, Streinu-Cercel, Adrian, Verheyen, Anke, Iraqi, Wafae, DeMasi, Ralph, Hill, Andrew, Lonjon-Domanec, Isabelle, Wedemeyer, Heiner
• Format: Journal Article
• Language: English
• Published: Netherlands 01.11.2014
• Subjects: Adult; Aged; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Drug Therapy, Combination; Female; Hepacivirus - classification; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Humans; Interferon-alpha - administration & dosage; Liver Cirrhosis - drug therapy; Liver Cirrhosis - virology; Male; Middle Aged; Oligopeptides - administration & dosage; Oligopeptides - therapeutic use; Polyethylene Glycols - administration & dosage; Recombinant Proteins - administration & dosage; Ribavirin - administration & dosage; Treatment Outcome; Young Adult; Cirrhosis; Telaprevir; Hepatitis C; Pegylated interferon
• DOI: 10.1016/j.jhep.2014.06.005

There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24). 1078 patients with bridging fibrosis (n=552) or cirrhosis (n=526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/mm(3), Hb >12/13 g/dl) and liver function (Albumin >3.3g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label. Overall, 614 (57%) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68% in 221 treatment naïve patients (62.8% F4), 72% in 356 prior relapsers (64.4% F4), 55% in 139 partial responders (53.2% F4), and 34% in 294 null responders (28.6% F4). The SVR24 rate to response-guided therapy (24 weeks treatment duration if undetectable viremia at weeks 4 and 12) was 84% in 222 naïve/relapser F3 patients. Independent predictors of response were: (A) F3 (odds ratio (OR)=1.51, 95% CI 1.31-2.00, p=0.005), (B) subtype 1b (OR=1.63, 95% CI 1.18-2.24, p=0.0029), (C) alpha-fetoprotein <10 ng/ml (OR=2.50, 95% CI 1.87-3.36, p<0.0001) and (D) any prior response other than null (OR=3.29, 95% CI 2.40-4.52, p<0.0001). SVR24 rose for patients who had more of these predictive factors: 6/32 (19%) for none, 38/139 (27%) for 1, 129/260 (50%) for 2, 202/329 (61%) for 3, and 194/235 (83%) for 4 factors. Grade 2-4 treatment-related adverse events (AE) were experienced by 719 (67%) patients; 169 (16%) discontinued therapy for AE and 7 (0.6%) died during the PR tail. Naïve and experienced patients with advanced fibrosis or cirrhosis due to HCV-1 who have compensated bone marrow and liver function, can effectively and safely be treated by TVR triple therapy. Baseline predictors of outcome have been identified to optimize pre-treatment counselling.